[ad_1]
Posted in:
In a statement released by the Russian Ministry of Health and the Russian Sovereign Fund involved in vaccine development, Russia confirmed Tuesday that its “Sputnik-V” corona virus vaccine, developed by the “Gamalia” Research Center in Moscow, it is 95% effective.
Moscow announced on Tuesday that its vaccine “Sputnik-V” anti-corona virus 95% effective. The Gamalia Research Center in Moscow, in collaboration with the Russian Ministry of Health and the Russian Sovereign Fund, involved in the development of the vaccine, announced in a statement that these are preliminary results of experiments on volunteers 42 days after the injection of the first dose. However, the number of cases used to calculate the efficacy rate was not mentioned.
The British laboratory, “AstraZeneca” and the University of Oxford announced Monday that their vaccine is nearly 70% effective.
The efficacy of the vaccine, developed by the “Pfizer / Biontech” alliance, was 95% effective in preventing Covid-19, according to the full results of a large-scale clinical trial announced last week.
For its part, the American company “Moderna” has announced similar results for its vaccine, with an efficacy rate of 94.5%.
The Russian sovereign wealth fund said in a separate statement that “the price of a dose of” Sputnik-V “for the international market will be less than ten dollars, indicating that the vaccine for Russian citizens will be free.
The “Sputnik-V” vaccine is currently in the third phase of clinical trials conducted according to an experimental approach in which neither the patient nor the doctor know whether the administered vaccine is real or placebo. The experiments include forty thousand volunteers.
At a time, Russia has not yet provided much scientific information on this vaccine, which Russian President Vladimir Putin boasts, but the developers of “Sputnik-V” confirmed Tuesday that the research will be published soon “in a major magazine. world medicine and will be subject to evaluation by the “developers.” Other vaccines.
The vaccine is based on “viral vectors” which are used as a vector in two injections of adenovirus (a very common virus mainly responsible for colds), which have been converted to be added to part of the emerging corona virus responsible for Covid infection. 19.
When modified adenovirus is injected into a person’s cells, that person produces a protein typical of SARS-Cove-2 that allows the immune system to recognize and fight it, according to the Gamalia Research Center.
Competition increases to develop a vaccine against the epidemic that has paralyzed entire countries since the beginning of the year.
Russia is determined to fight the race to find a vaccine at the forefront and has announced since August, ahead of large-scale clinical trials, the effectiveness of its vaccine, which has raised doubts in the international scientific community.
France 24 / AFP
.
[ad_2]
Source link
